SHATTUCK LABS INC (STTK) Stock Price, Quote, News and Overview
NASDAQ:STTK - Nasdaq - US82024L1035 - Common Stock - Currency: USD
STTK Quote, Performance and Key Statistics
NASDAQ:STTK (5/21/2025, 11:42:52 AM)
1.03
0 (0%)
The current stock price of STTK is 1.03 USD. In the past month the price increased by 15.33%. In the past year, price decreased by -86.25%.
STTK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.9 | 325.26B | ||
| AMGN | AMGEN INC | 13.18 | 147.10B | ||
| GILD | GILEAD SCIENCES INC | 14.03 | 135.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.00B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.75 | 65.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.63B | ||
| ARGX | ARGENX SE - ADR | 100.97 | 36.19B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.68B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.88B | ||
| NTRA | NATERA INC | N/A | 20.87B | ||
| BIIB | BIOGEN INC | 8.1 | 18.78B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.71B |
Related stock screener links
About STTK
Company Profile
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. The company is headquartered in Austin, Texas and currently employs 44 full-time employees. The company went IPO on 2020-10-09. The firm is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The firm is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. The company is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Company Info
SHATTUCK LABS INC
500 W. 5Th Street, Suite 100
Austin TEXAS 78703 US
CEO: Taylor Schreiber
Employees: 44
Phone: 15129004690
SHATTUCK LABS INC / STTK FAQ
What is the stock price of SHATTUCK LABS INC today?
The current stock price of STTK is 1.03 USD.
What is the ticker symbol for SHATTUCK LABS INC stock?
The exchange symbol of SHATTUCK LABS INC is STTK and it is listed on the Nasdaq exchange.
On which exchange is STTK stock listed?
STTK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SHATTUCK LABS INC stock?
11 analysts have analysed STTK and the average price target is 2.51 USD. This implies a price increase of 143.61% is expected in the next year compared to the current price of 1.03. Check the SHATTUCK LABS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SHATTUCK LABS INC worth?
SHATTUCK LABS INC (STTK) has a market capitalization of 49.34M USD. This makes STTK a Nano Cap stock.
How many employees does SHATTUCK LABS INC have?
SHATTUCK LABS INC (STTK) currently has 44 employees.
What are the support and resistance levels for SHATTUCK LABS INC (STTK) stock?
SHATTUCK LABS INC (STTK) has a support level at 0.9 and a resistance level at 1.11. Check the full technical report for a detailed analysis of STTK support and resistance levels.
Is SHATTUCK LABS INC (STTK) expected to grow?
The Revenue of SHATTUCK LABS INC (STTK) is expected to decline by -100% in the next year. Check the estimates tab for more information on the STTK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SHATTUCK LABS INC (STTK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of STTK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of STTK, evaluating the profitability, health, valuation and growth aspects
- SHATTUCK LABS INC (STTK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SHATTUCK LABS INC (STTK) Sales and EPS estimates to see what analysts future expectations are.
- SHATTUCK LABS INC (STTK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SHATTUCK LABS INC (STTK) Insider and Institutional Ownership to learn about the owners and their transactions.
- SHATTUCK LABS INC (STTK) Stock Chart to make your own analysis
- SHATTUCK LABS INC (STTK) Latest news and press-releases to stay up to date.
Does SHATTUCK LABS INC (STTK) stock pay dividends?
STTK does not pay a dividend.
When does SHATTUCK LABS INC (STTK) report earnings?
SHATTUCK LABS INC (STTK) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of SHATTUCK LABS INC (STTK)?
SHATTUCK LABS INC (STTK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.39).
What is the Short Interest ratio of SHATTUCK LABS INC (STTK) stock?
The outstanding short interest for SHATTUCK LABS INC (STTK) is 3.96% of its float. Check the ownership tab for more information on the STTK short interest.
STTK Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to STTK. When comparing the yearly performance of all stocks, STTK is a bad performer in the overall market: 95.98% of all stocks are doing better.
STTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to STTK. While STTK seems to be doing ok healthwise, there are quite some concerns on its profitability.
STTK Financial Highlights
Over the last trailing twelve months STTK reported a non-GAAP Earnings per Share(EPS) of -1.39. The EPS increased by 27.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -91.5% | ||
| ROE | -104.47% | ||
| Debt/Equity | 0 |
STTK Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to STTK. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 34.45% and a revenue growth -100% for STTK